Latest Content

University of Virginia Health is tracking efgartigimod durability in generalized myasthenia gravis and how pharmacists help patients get past barriers.

NCCN now lists the brain-penetrant ROS1 inhibitor after progression on earlier TKIs, including as a preferred option for symptomatic brain progression.

KFF finds 4.3 million Medicare beneficiaries will lose their MA or stand-alone Part D plans at the end of 2026, as PDP options keep shrinking.

Anti-CGRP antibody exposure near conception was linked to higher spontaneous abortion risk in migraine, while propranolol was not, a cohort study found.

Combined MRI and ultrasound raised sensitivity for bowel and uterosacral ligament endometriosis but reduced specificity in a prospective cohort study.

The Cambridge Multimorbidity Score was adapted to ICD-10 and demonstrated better predictive performance than the Charlson Comorbidity Index in German primary care claims data.

Asia-Pacific Delphi Consensus updates alopecia areata clinical guidelines for trichoscopy, SALT Score severity, and first-line JAK inhibitors.

Biomarker testing, treatment sequencing, drug delivery, and rural access barriers were examined during an IVBM event in Salt Lake City.

Experts spot idiopathic hypersomnia when tests miss it, using symptom scales, targeted questions, wearables, and shared treatment choices.